Jen-Tsan Chi, Chao Chieh Lin, Yi-Tzu Lin, Ssu-Yu Chen, Yasaman Setayeshpour, Yubin Chen, Denise Dunn, Erik Soderblom, Guo-Fang Zhang, Valeriy Filonenko, Suh Young Jeong, Scott Floyd, Susan Hayflick, Ivan Gout
{"title":"辅酶 A 通过辅佐硫代氧化还原酶 2 防止铁中毒。","authors":"Jen-Tsan Chi, Chao Chieh Lin, Yi-Tzu Lin, Ssu-Yu Chen, Yasaman Setayeshpour, Yubin Chen, Denise Dunn, Erik Soderblom, Guo-Fang Zhang, Valeriy Filonenko, Suh Young Jeong, Scott Floyd, Susan Hayflick, Ivan Gout","doi":"10.21203/rs.3.rs-4522617/v1","DOIUrl":null,"url":null,"abstract":"<p><p>The Cystine-xCT transporter-Glutathione (GSH)-GPX4 axis is the canonical pathway to protect against ferroptosis. While not required for ferroptosis-inducing compounds (FINs) targeting GPX4, FINs targeting the xCT transporter require mitochondria and its lipid peroxidation to trigger ferroptosis. However, the mechanism underlying the difference between these FINs is still unknown. Given that cysteine is also required for coenzyme A (CoA) biosynthesis, here we show that CoA supplementation specifically prevents ferroptosis induced by xCT inhibitors but not GPX4 inhibitors. We find that, auranofin, a thioredoxin reductase inhibitor, abolishes the protective effect of CoA. We also find that CoA availability determines the enzymatic activity of thioredoxin reductase, but not thioredoxin. Importantly, the mitochondrial thioredoxin system, but not the cytosolic thioredoxin system, determines CoA-mediated ferroptosis inhibition. Our data show that the CoA regulates the <i>in vitro</i> enzymatic activity of mitochondrial thioredoxin reductase (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolishes its <i>in vitro</i> enzymatic activity and ability to protect cells from ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2, an effect that was rescued by CoA supplementation. Furthermore, the fibroblasts from patients with disrupted CoA metabolism demonstrate increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis leads to an oxidized thioredoxin system, mitochondrial lipid peroxidation, and loss in cell viability, which were all rescued by ferrostatin-1. These findings identify CoA-mediated post-translation modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.</p>","PeriodicalId":94282,"journal":{"name":"Research square","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213209/pdf/","citationCount":"0","resultStr":"{\"title\":\"Coenzyme A protects against ferroptosis via CoAlation of thioredoxin reductase 2.\",\"authors\":\"Jen-Tsan Chi, Chao Chieh Lin, Yi-Tzu Lin, Ssu-Yu Chen, Yasaman Setayeshpour, Yubin Chen, Denise Dunn, Erik Soderblom, Guo-Fang Zhang, Valeriy Filonenko, Suh Young Jeong, Scott Floyd, Susan Hayflick, Ivan Gout\",\"doi\":\"10.21203/rs.3.rs-4522617/v1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Cystine-xCT transporter-Glutathione (GSH)-GPX4 axis is the canonical pathway to protect against ferroptosis. While not required for ferroptosis-inducing compounds (FINs) targeting GPX4, FINs targeting the xCT transporter require mitochondria and its lipid peroxidation to trigger ferroptosis. However, the mechanism underlying the difference between these FINs is still unknown. Given that cysteine is also required for coenzyme A (CoA) biosynthesis, here we show that CoA supplementation specifically prevents ferroptosis induced by xCT inhibitors but not GPX4 inhibitors. We find that, auranofin, a thioredoxin reductase inhibitor, abolishes the protective effect of CoA. We also find that CoA availability determines the enzymatic activity of thioredoxin reductase, but not thioredoxin. Importantly, the mitochondrial thioredoxin system, but not the cytosolic thioredoxin system, determines CoA-mediated ferroptosis inhibition. Our data show that the CoA regulates the <i>in vitro</i> enzymatic activity of mitochondrial thioredoxin reductase (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolishes its <i>in vitro</i> enzymatic activity and ability to protect cells from ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2, an effect that was rescued by CoA supplementation. Furthermore, the fibroblasts from patients with disrupted CoA metabolism demonstrate increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis leads to an oxidized thioredoxin system, mitochondrial lipid peroxidation, and loss in cell viability, which were all rescued by ferrostatin-1. These findings identify CoA-mediated post-translation modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.</p>\",\"PeriodicalId\":94282,\"journal\":{\"name\":\"Research square\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213209/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research square\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21203/rs.3.rs-4522617/v1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research square","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21203/rs.3.rs-4522617/v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
胱氨酸-xCT转运体-谷胱甘肽(GSH)-GPX4轴是防止铁变态反应的典型途径。以 GPX4 为靶点的铁氧化诱导化合物(FINs)不需要胱氨酸,而以 xCT 转运体为靶点的 FINs 则需要线粒体及其脂质过氧化反应来触发铁氧化。然而,这些 FINs 之间存在差异的机制尚不清楚。鉴于辅酶 A(CoA)的生物合成也需要半胱氨酸,我们在此表明,CoA 的补充能特异性地防止 xCT 抑制剂而非 GPX4 抑制剂诱导的铁中毒。我们发现,硫代氧化还原酶抑制剂 Auranofin 可取消 CoA 的保护作用。我们还发现,CoA 的可用性决定了硫氧还蛋白还原酶的酶活性,而不是硫氧还蛋白。重要的是,线粒体硫氧还蛋白系统,而不是细胞质硫氧还蛋白系统,决定了 CoA 介导的铁突变抑制作用。我们的数据显示,CoA 通过共价修饰 Cys-483 上半胱氨酸的硫醇基团(CoAlation)来调节线粒体硫氧还原酶(TXNRD2)的体外酶活性。用丙氨酸取代Cys-483后,TXNRD2的体外酶活性和保护细胞免于铁中毒的能力就会消失。以 xCT 为靶点限制半胱氨酸的输入,从而限制 CoA 的生物合成,减少了 TXNRD2 上的 CoAlation,补充 CoA 后这种效应得到了缓解。此外,CoA 代谢紊乱患者的成纤维细胞显示线粒体脂质过氧化增加。在器官型脑片培养中,抑制 CoA 的生物合成会导致硫氧化还原酶系统氧化、线粒体脂质过氧化和细胞活力丧失,而铁前列素-1 则可挽救这些现象。这些研究结果表明,CoA 介导的翻译后修饰调节硫代毒素系统是一种替代性铁氧化保护途径,对 CoA 代谢紊乱的患者具有潜在的临床意义。
Coenzyme A protects against ferroptosis via CoAlation of thioredoxin reductase 2.
The Cystine-xCT transporter-Glutathione (GSH)-GPX4 axis is the canonical pathway to protect against ferroptosis. While not required for ferroptosis-inducing compounds (FINs) targeting GPX4, FINs targeting the xCT transporter require mitochondria and its lipid peroxidation to trigger ferroptosis. However, the mechanism underlying the difference between these FINs is still unknown. Given that cysteine is also required for coenzyme A (CoA) biosynthesis, here we show that CoA supplementation specifically prevents ferroptosis induced by xCT inhibitors but not GPX4 inhibitors. We find that, auranofin, a thioredoxin reductase inhibitor, abolishes the protective effect of CoA. We also find that CoA availability determines the enzymatic activity of thioredoxin reductase, but not thioredoxin. Importantly, the mitochondrial thioredoxin system, but not the cytosolic thioredoxin system, determines CoA-mediated ferroptosis inhibition. Our data show that the CoA regulates the in vitro enzymatic activity of mitochondrial thioredoxin reductase (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolishes its in vitro enzymatic activity and ability to protect cells from ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2, an effect that was rescued by CoA supplementation. Furthermore, the fibroblasts from patients with disrupted CoA metabolism demonstrate increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis leads to an oxidized thioredoxin system, mitochondrial lipid peroxidation, and loss in cell viability, which were all rescued by ferrostatin-1. These findings identify CoA-mediated post-translation modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.